for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Zimmer Biomet Holdings Inc

ZBH.N

Latest Trade

135.24USD

Change

-1.20(-0.88%)

Volume

220,569

Today's Range

134.64

 - 

137.19

52 Week Range

97.00

 - 

143.24

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
136.44
Open
136.19
Volume
220,569
3M AVG Volume
25.09
Today's High
137.19
Today's Low
134.64
52 Week High
143.24
52 Week Low
97.00
Shares Out (MIL)
205.31
Market Cap (MIL)
28,013.11
Forward P/E
17.44
Dividend (Yield %)
0.70

Next Event

Q3 2019 Zimmer Biomet Holdings Inc Earnings Release

Latest Developments

More

Zimmer Biomet Statement on ROSA Brain 3.0 Field Action

Zimmer Biomet Announces Second Quarter Adjusted Earnings Per Share Of $1.93

Zimmer Biomet Announces Chief Financial Officer Transition Plan

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Zimmer Biomet Holdings Inc

Zimmer Biomet Holdings, Inc. is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products. The Company's products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. The Company manages its operations through three geographic operating segments: the Americas, consisting principally of the United States and other North, Central and South American markets; EMEA, consisting principally of Europe and the Middle East and African markets, and Asia Pacific, consisting primarily of Japan and other Asian and Pacific markets. The Company's product category segments include Americas Spine, Office Based Technologies, Craniomaxillofacial and Thoracic (CMF), and Dental.

Industry

Medical Equipment & Supplies

Contact Info

345 E Main St

+1.574.2676131

http://www.zimmerbiomet.com/

Executive Leadership

Larry C. Glasscock

Independent Non-Executive Chairman of the Board

Bryan C. Hanson

President, Chief Executive Officer, Director

Suketu P. Upadhyay

Chief Financial Officer, Executive Vice President

Aure Bruneau

Group President, Spine, CMF, Thoracic and Surgery Assisting Technology

Ivan Tornos

Group President, Orthopedics

Key Stats

1.93 mean rating - 29 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

7.7K

2017

7.8K

2018

7.9K

2019(E)

8.0K
EPS (USD)

2016

7.960

2017

8.030

2018

7.640

2019(E)

7.821
Price To Earnings (TTM)
--
Price To Sales (TTM)
3.56
Price To Book (MRQ)
2.40
Price To Cash Flow (TTM)
42.31
Total Debt To Equity (MRQ)
74.70
LT Debt To Equity (MRQ)
57.54
Return on Investment (TTM)
-1.60
Return on Equity (TTM)
-1.42

Latest News

Latest News

Appeals court upholds $254 million patent verdict for Stryker against Zimmer

A federal appeals court on Monday upheld a $254 million patent infringement verdict Stryker Corp won against rival medical device maker Zimmer Biomet Holdings Inc, bringing a likely end to a long-running court battle that previously ended up before the U.S. Supreme Court.

Sales reps can pursue overtime lawsuit against Zimmer Biomet - ruling

Medical device maker Zimmer Biomet must face a lawsuit accusing it of denying overtime pay to sales representatives across the country by misclassifying them as independent contractors, a federal judge in San Francisco ruled.

Hip and knee surgeons to use Apple Watch to monitor patients

Up to 10,000 Americans due to have hip or knee replacements will be able to funnel basic health data directly from their Apple Watches to their surgeons under a new app being tested by orthopedics company Zimmer Biomet.

Hip and knee surgeons to use Apple Watch to monitor patients

Up to 10,000 Americans due to have hip or knee replacements will be able to funnel basic health data directly from their Apple Watches to their surgeons under a new app being tested by prosthetic limb specialist Zimmer Biomet .

BRIEF-Zimmer Biomet Holdings Announces 510(K) Clearance For Zyston Strut Open Titanium Interbody Spacer System

* ZIMMER BIOMET HOLDINGS ANNOUNCES 510(K) CLEARANCE FOR ZYSTON STRUT OPEN TITANIUM INTERBODY SPACER SYSTEM Source text for Eikon: Further company coverage:

BRIEF-Zimmer Biomet Reports Q1 Earnings Per Share $0.85

* ZIMMER BIOMET ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Zimmer Biomet Announces FDA Clearance And First Surgical Case Of The Persona Trabecular Metal Tibia

* ZIMMER BIOMET ANNOUNCES FDA CLEARANCE AND FIRST SURGICAL CASE OF THE PERSONA® TRABECULAR METAL™ TIBIA

BRIEF-Zimmer Biomet Says CEO Hanson's FY'17 Total Compensation Was $16.3 Mln

* ZIMMER BIOMET SAYS CEO BRYAN HANSON'S FY 2017 TOTAL COMPENSATION WAS $16.3 MLN - SEC FILING

Zimmer beats knee implant bellwether case on appeal

A Pepsi bottling plant worker has lost his bid to revive a lawsuit claiming Zimmer Biomet Holdings Inc failed to warn that its NexGen knee implants were prone to premature loosening in patients who engage in activities that need knee flexibility.

BRIEF-Zimmer Biomet Holdings Files For Offering Of Floating Rate Notes Due 2021

* ZIMMER BIOMET HOLDINGS INC - FILES FOR OFFERING OF FLOATING RATE NOTES DUE 2021 AND NOTES DUE 2023 - SEC FILING Source text: (http://bit.ly/2tzlxYD) Further company coverage:

BRIEF-Zimmer Biomet Holdings Reports Q4 EPS Of $6.16

* ZIMMER BIOMET ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2017 RESULTS

BRIEF-Zimmer Biomet Holdings Announces FDA Clearance Of Sidus Stem-Free Shoulder System

* ZIMMER BIOMET HOLDINGS SAYS THE SIDUS SYSTEM WILL BE AVAILABLE IN U.S BEGINNING IN Q1 OF 2018 Source text for Eikon: Further company coverage:

BRIEF-Zimmer Biomet Says Positive Results From Progress II Trial Of Autologous Protein Solution Prepared With nSTRIDE Aps Kit In Treating Osteoarthritis

* ZIMMER BIOMET HOLDINGS- POSITIVE RESULTS FROM PROGRESS II TRIAL OF AUTOLOGOUS PROTEIN SOLUTION PREPARED WITH NSTRIDE APS KIT IN TREATING OSTEOARTHRITIS Source text for Eikon: Further company coverage:

BRIEF-Zimmer Biomet Names Bryan Hanson CEO

* ZIMMER BIOMET ANNOUNCES APPOINTMENT OF BRYAN C. HANSON AS PRESIDENT AND CHIEF EXECUTIVE OFFICER

BRIEF-Zimmer Biomet Holdings Q3 adjusted earnings per share $1.72

* Q3 earnings per share view $1.74 -- Thomson Reuters I/B/E/S

BRIEF-ZIMMER BIOMET ‍ANNOUNCES U.S. LAUNCH OF VITALITY+, VITAL SPINAL FIXATION SYSTEMS​

* ANNOUNCES U.S. LAUNCH OF VITALITY+ AND VITAL SPINAL FIXATION SYSTEMS Source text for Eikon: Further company coverage:

BRIEF-Zimmer Biomet announces U.S. launch of avenue T TLIF Cage with integrated vertebridge plating

* Zimmer Biomet announces U.S. launch of avenue T TLIF Cage with integrated vertebridge plating

BRIEF-Zimmer Biomet says its unit entered into term loan agreement with Sumitomo Mitsui Banking Corp, for new ¥21.3 bln term loan​ - SEC Filing

* Zimmer Biomet says on Sept 22, unit entered into term loan agreement with Sumitomo Mitsui Banking Corporation, for new ¥21.3 billion term loan - SEC Filing

BRIEF-Zimmer Biomet ‍announces global launch of persona partial knee system​

* Zimmer Biomet Holdings Inc announces global launch of persona partial knee system Source text for Eikon: Further company coverage:

BRIEF-Jana Partners takes sole share stake in Altaba, Pandora, Zimmer Biomet

* Takes sole share stake of 3.3 million shares in Altaba Inc - SEC filing

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up